Repurposing N,N-dimethylacetamide (DMA), a pharmaceutical excipient, as a prototype novel anti-inflammatory agent for the prevention and/or treatment of preterm birth

Samir Gorasiya, Juliet Mushi, Ryan Pekson, Sabesan Yoganathan, Sandra E. Reznik

Research output: Contribution to journalReview article

3 Scopus citations


Background: Preterm birth (PTB), or birth that occurs before 37 weeks of gestation, accounts for the majority of perinatal morbidity and mortality. As of 2016, PTB has an occurrence rate of 9.6% in the United States and accounts for up to 18 percent of births worldwide. Inflammation has been identified as the most common cause of PTB, but effective pharmacotherapy has yet to be developed to prevent inflammation driven PTB. Our group has discovered that N,N-dimethylacetamide (DMA), a readily available solvent commonly used as a pharmaceutical excipient, rescues lipopolysaccharide (LPS)-induced timed pregnant mice from PTB. Methods: We have used in vivo, ex vivo and in vitro approaches to investigate this compound further. Results: Interestingly, we found that DMA suppresses cytokine secretion by inhibiting nuclear factor-kappa B (NF-κB). In ongoing work in this exciting line of investigation, we are currently investigating structural analogs of DMA, some of them novel, to optimize this approach focused on the inflammation associated with PTB. Conclusion: Successful development of pharmacotherapy for the prevention of PTB rests upon the pursuit of multiple strategies to solve this important clinical challenge.

Original languageEnglish (US)
Pages (from-to)989-992
Number of pages4
JournalCurrent pharmaceutical design
Issue number9
StatePublished - Jan 1 2018



  • Gestation
  • Inflammation
  • Lipopolysaccharide
  • N,N-dimethylacetamide
  • Nuclear factor kappa B
  • Preterm birth

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this